Drug Profile
OPS 2071
Alternative Names: OPS-2071Latest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class Anti-infectives; Anti-inflammatories; Fluoroquinolones; Irritable bowel syndrome therapies
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome
- Discontinued Clostridium difficile infections; Crohn's disease; Intestinal infections
Most Recent Events
- 02 Aug 2023 Phase-II clinical trials in Irritable bowel syndrome in China (PO) (NCT05923892)
- 28 Jun 2023 Otsuka Beijing Research Institute plans a phase II trial for Irritable bowel syndrome in China (PO) in July 2023 (NCT05923892)
- 27 Sep 2022 Discontinued - Phase-II for Crohn's disease (Adjunctive treatment, In the elderly, In adults) in Germany (PO)